Estimated response rates and duration of response for different responder indices
| Responder index | Landmark response rate at 52 weeks* | Probability in response at 52 weeks from MSM(95% CI) | Mean sojourn time in response(95% CI) | Mean total time in response(95% CI) |
| SRI-4 | 45.9% (95% CI 42.3% to 49.5%) | 61.0% (95% CI 58.3% to 63.5%) | 31.5 weeks (95% CI 28.5 to 34.8) | 24.8 weeks (95% CI 23.7 to 25.9) |
| SRI-5 | 33.6% (95% CI 30.2% to 37.1%) | 43.6% (95% CI 40.8% to 46.3%) | 25.7 weeks (95% CI 23.1 to 28.7) | 17.1 weeks (95% CI 16.0 to 18.1) |
| SRI-6 | 32.5% (95% CI 29.2% to 36.0%) | 41.7% (95% CI 38.8% to 44.7%) | 24.3 weeks (95% CI 21.9 to 27.1) | 16.4 weeks (95% CI 15.3 to 17.5) |
| BICLA† | 38.0% (95% CI 33.4% to 42.7%) | 50.2% (95% CI 47.1% to 53.5%) | 20.4 weeks(95% CI 18.1 to 23.0) | 21.2 weeks(95% CI 19.7 to 22.5) |
*Dropouts and missing data imputed as non-response.
†Among patients with 1A or ≥2B at baseline.
BICLA, BILAG-based Composite Lupus Assessment; MSM, multistate model; SRI, SLE Responder Index.